Skip to main content

Table 2 PFS and Quality Adjusted PFS (QA-PFS) in months (mean and 95% CrI)

From: Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

 

Pac/Carb

Gem/Cis

Pem/Cis

Gefitinib

PFS duration (months)

6.7 (5.9; 7.4)

7.0 (6.1; 7.9)

7.2 (6.2; 8.2)

10.5 (8.9; 12.6)

QA-PFS (months)

4.9 (4.4; 5.5)

5.2 (4.5; 5.8)

5.3 (4.6; 6.1)

8.3 (7.0; 9.9)

ΔQA-PFS with gefitinib (months)

3.4 (2.4; 4.8)

3.2 (2.0; 4.6)

3.0 (1.9; 4.4)

-